ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2018
A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer.
Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes.Frontiers in pharmacology · 2023Pooled it
- Heterometallic Multinuclear Ruthenium Complexes as Cytotoxic Agents.Biomedicines · 2026Review
- High Cytotoxicity of Ruthenium(II) and Gold(I) Bimetallic Complexes and Its Precursors.Inorganic chemistry · 2026Article
- Review of the Most Important Research Trends in Potential Chemotherapeutics Based on Coordination Compounds of Ruthenium, Rhodium and Iridium.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- A Ru(II)-Strained Complex with 2,9-Diphenyl-1,10-phenanthroline Ligand Induces Selective Photoactivatable Chemotherapeutic Activity on Human Alveolar Carcinoma Cells via Apoptosis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- 5-Nitrofuryl-Containing Thiosemicarbazone Gold(I) Compounds: Synthesis, Stability Studies, and Anticancer Activity.ChemPlusChem · 2023Article
- Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Article
- Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications.Chemical reviews · 2023Review
- Promising heterometallic compounds as anticancer agents: Recent studies in vivo.Current opinion in chemical biology · 2023Review
- Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments.Molecules (Basel, Switzerland) · 2022Review
- Metallodrugs: an approach against invasion and metastasis in cancer treatment.FEBS open bio · 2022Review
- Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques.RSC medicinal chemistry · 2022Review
- Gold Compounds and the Anticancer Immune Response.Frontiers in pharmacology · 2021Review
- Auranofin-Based Analogues Are Effective Against Clear Cell Renal CarcinomaACS pharmacology & translational science · 2020Article
- Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype.Cancers · 2020Article
- SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020Article
- Recent Advances of Gold Compounds in Anticancer Immunity.Frontiers in chemistry · 2020Review
- Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct metal species into a single molecule. The ruthenium-gold (Ru-Au) family of compounds based on Au-N-heterocyclic carbene (NHC) fragments [Cl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.